Therapeutic targeting of IL-17 for psoriasis
نویسندگان
چکیده
منابع مشابه
IL-17 Blockade in Psoriasis
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
متن کاملTherapeutic potential of targeting IL-17 and IL-23 in sepsis
Severe sepsis is a major concern of public health in industrialized countries. It is estimated that in the United States 200,000-400,000 cases occur annually and resulting in an extensive burden for the health care systems. To date, no FDA-approved pharmacologic agents for the treatment or prevention of human sepsis are available. The current modalities of therapy in sepsis include the standard...
متن کاملTargeting IL-17 for pancreatic cancer prevention
It is well known that pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, which can be explained by both an inherently aggressive biology and a lack of effective chemotherapeutics. As a result, there is strong rationale for the development of effective preventive interventions in high risk populations. Chronic pancreatitis increases the risk of developing PDAC more than fifteen fold...
متن کاملA Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
• Interleukin (IL)-23 and IL-17 play an important role in the development of psoriasis. • Many of the new biologic drugs targeting IL-23 and IL-17 have been shown to be both safe and effective in treating moderate-to-severe plaque psoriasis. Long-term safety data still need to be established. • These drugs are more selective with inhibition of " downstream " targets in the immunopathogenesis of...
متن کاملRole of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine or associated receptors. Ixekizumab is a subcutaneously administered humanized monoclonal antibody, which acts to neutralize IL-17A. This articl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Immunology
سال: 2012
ISSN: 1474-1733,1474-1741
DOI: 10.1038/nri3220